scholarly journals Development and Validation of a Combined Ferroptosis and Immune Prognostic Classifier for Hepatocellular Carcinoma

Author(s):  
Yang Liu ◽  
Xi Zhang ◽  
Junjun Zhang ◽  
Juan Tan ◽  
Jie Li ◽  
...  

BackgroundImmunotherapy and sorafenib exert anti-tumor effects via ferroptosis, but reliable biomarkers for the individual treatment and prognosis prediction of hepatocellular carcinoma (HCC) based on the ferroptosis and immune status remain lacking.MethodsFerroptosis-related genes (FRGs) were identified by downloading data from FerrDb and by searching and reading original articles from PubMed. Immune-related genes (IRGs) were downloaded from ImmPort. Prognostic FRGs and IRGs in the GSE14520 (n = 220) and The Cancer Genome Atlas (TCGA, n = 365) datasets were identified. Least absolute shrinkage and selection operator (LASSO) Cox regression and multivariate Cox regression were used for model construction. Ferroptosis expression profiles, the infiltration of immune cells, and the somatic mutation status were analyzed and compared.ResultsTwenty-seven prognostic ferroptosis- and immune-related signatures were included to construct a comprehensive index of ferroptosis and immune status (CIFI). A subgroup of patients was identified as having a high CIFI value, which was associated with a worse prognosis. This subgroup of patients had significantly up-regulated expressions of many suppressors of ferroptosis and higher fractions of immunosuppressive cells, such as cancer-associated fibroblasts (CAFs) and myeloid-derived suppressor cells (MDSCs). Notably, somatic mutation analysis indicated that high-CIFI patients had higher levels of tumor heterogeneity and higher mutation frequencies of genes like TP53.ConclusionIn this work, a novel prognostic classifier was developed based on ferroptosis- and IRGs in HCC, and this classifier could be used for prognostic prediction and the selection of patients for immunotherapies and targeted therapies.

2021 ◽  
Vol 12 ◽  
Author(s):  
Shenglan Cai ◽  
Xingwang Hu ◽  
Ruochan Chen ◽  
Yiya Zhang

BackgroundEnhancer RNAs (eRNAs) are intergenic long non-coding RNAs (lncRNAs) that participate in the progression of malignancies by targeting tumor-related genes and immune checkpoints. However, the potential role of eRNAs in hepatocellular carcinoma (HCC) is unclear. In this study, we aimed to construct an immune-related eRNA prognostic model that could be used to prospectively assess the prognosis of patients with HCC.MethodsGene expression profiles of patients with HCC were downloaded from The Cancer Genome Atlas (TCGA). The eRNAs co-expressed from immune genes were identified as immune-related eRNAs. Cox regression analyses were applied in a training cohort to construct an immune-related eRNA signature (IReRS), that was subsequently used to analyze a testing cohort and combination of the two cohorts. Kaplan-Meier and receiver operating characteristic (ROC) curves were used to validate the predictive effect in the three cohorts. Gene Set Enrishment Analysis (GSEA) computation was used to identify an IReRS-related signaling pathway. A web-based cell type identification by estimating relative subsets of RNA transcripts (CIBERSORT) computation was used to evaluate the relationship between the IReRS and infiltrating immune cells.ResultsA total of sixty-four immune-related eRNAs (IReRNAs) was identified in HCC, and 14 IReRNAs were associated with overall survival (OS). Five IReRNAs were used for constructing an immune-related eRNA signature (IReRS), which was shown to correlate with poor survival and to be an independent prognostic biomarker for HCC. The GSEA results showed that the IReRS was correlated to cancer-related and immune-related pathways. Moreover, we found that IReRS was correlated to infiltrating immune cells, including CD8+ T cells and M0 macrophages. Finally, differential expressions of the five risk IReRNAs in tumor tissues vs. adjacent normal tissues and their prognostic values were verified, in which the AL445524.1 may function as an oncogene that affects prognosis partly by regulating CD4-CLTA4 related genes.ConclusionOur results suggest that the IReRS could serve as a biomarker for predicting prognosis in patients with HCC. Additionally, it may be correlated to the tumor immune microenvironment and could also be used as a biomarker in immunotherapy for HCC.


Author(s):  
Dafeng Xu ◽  
Yu Wang ◽  
Jincai Wu ◽  
Yuliang Zhang ◽  
Zhehao Liu ◽  
...  

Background: The prognosis of patients with hepatocellular carcinoma (HCC) is negatively affected by the lack of effective prognostic indicators. The change of tumor immune microenvironment promotes the development of HCC. This study explored new markers and predicted the prognosis of HCC patients by systematically analyzing immune characteristic genes.Methods: Immune-related genes were obtained, and the differentially expressed immune genes (DEIGs) between tumor and para-cancer samples were identified and analyzed using gene expression profiles from TCGA, HCCDB, and GEO databases. An immune prognosis model was also constructed to evaluate the predictive performance in different cohorts. The high and low groups were divided based on the risk score of the model, and different algorithms were used to evaluate the tumor immune infiltration cell (TIIC). The expression and prognosis of core genes in pan-cancer cohorts were analyzed, and gene enrichment analysis was performed using clusterProfiler. Finally, the expression of the hub genes of the model was validated by clinical samples.Results: Based on the analysis of 730 immune-related genes, we identified 64 common DEIGs. These genes were enriched in the tumor immunologic related signaling pathways. The first 15 genes were selected using RankAggreg analysis, and all the genes showed a consistent expression trend across multi-cohorts. Based on lasso cox regression analysis, a 5-gene signature risk model (ATG10, IL18RAP, PRKCD, SLC11A1, and SPP1) was constructed. The signature has strong robustness and can stabilize different cohorts (TCGA-LIHC, HCCDB18, and GSE14520). Compared with other existing models, our model has better performance. CIBERSORT was used to assess the landscape maps of 22 types of immune cells in TCGA, GSE14520, and HCCDB18 cohorts, and found a consistent trend in the distribution of TIIC. In the high-risk score group, scores of Macrophages M1, Mast cell resting, and T cells CD8 were significantly lower than those of the low-risk score group. Different immune expression characteristics, lead to the different prognosis. Western blot demonstrated that ATG10, PRKCD, and SPP1 were highly expressed in cancer tissues, while IL18RAP and SLC11A1 expression in cancer tissues was lower. In addition, IL18RAP has a highly positive correlation with B cell, macrophage, Neutrophil, Dendritic cell, CD8 cell, and CD4 cell. The SPP1, PRKCD, and SLC11A1 genes have the strongest correlation with macrophages. The expression of ATG10, IL18RAP, PRKCD, SLC11A1, and SPP1 genes varies among different immune subtypes and between different T stages.Conclusion: The 5-immu-gene signature constructed in this study could be utilized as a new prognostic marker for patients with HCC.


2020 ◽  
Vol 10 ◽  
Author(s):  
Quanwei Zhou ◽  
Xuejun Yan ◽  
Weidong Liu ◽  
Wen Yin ◽  
Hongjuan Xu ◽  
...  

Diffuse glioma is one of the most prevalent malignancies of the brain, with high heterogeneity of tumor-infiltrating immune cells. However, immune-associated subtypes of diffuse glioma have not been determined, nor has the effect of different immune-associated subtypes on disease prognosis and immune infiltration of diffuse glioma patients. We retrieved the expression profiles of immune-related genes from The Cancer Genome Atlas (TCGA) (n = 672) and GSE16011 (n = 268) cohorts and used them to identify subtypes of diffuse glioma via Consensus Cluster Plus analysis. We used the limma, clusterProfiler, ESTIMATE, and survival packages of R for differential analysis, functional enrichment, immune and stromal score evaluation respectively in three subtypes, and performed log-rank tests in immune subtypes of diffuse glioma. The immune-associated features of diffuse glioma in the two cohorts were characterized via bioinformatic analyses of the mRNA expression data of immune-related genes. Three subtypes (C1–3) of diffuse glioma were identified from TCGA data, and were verified using the GSE16011 cohort. We then evaluated their immune characteristics and clinical features. Our mRNA profiling analyses indicated that the different subtypes of diffuse glioma presented differential expression profile of specific genes and signal pathways in the TCGA cohort. Patients with subtype C1, who were mostly diagnosed with grade IV glioma, had poorer outcomes than patients with subtype C2 or C3. Subtype C1 was characterized by a higher degree of immune cell infiltration as estimated by GSVA, and more frequent wildtype IDH1. By contrast, subtype C3 included more grade II and IDH1-mutated glioma, and was associated with more infiltration of CD4+T cells. Most subtype C2 had the features between subtypes C1 and C3. Meanwhile, immune checkpoints and their ligand molecules, including PD1/(PD-L1/PDL2), CTLA4/(CD80/CD86), and B7H3/TLT2, were significantly upregulated in subtype C1 and downregulated in subtype C3. In addition, patients with subtype C1 exhibited more frequent gene mutations. Univariate and multivariate Cox regression analyses revealed that diffuse glioma subtype was an effective, independent, and better prognostic factor. Therefore, we established a novel immune-related classification of diffuse glioma, which provides potential immunotherapy targets for diffuse glioma.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Lunxu Li ◽  
Shilin Xia ◽  
Xueying Shi ◽  
Xu Chen ◽  
Dong Shang

AbstractHepatocellular carcinoma (HCC) is one of the main causes of cancer deaths globally. Immunotherapy is becoming increasingly important in the cure of advanced HCC. Thus it is essential to identify biomarkers for treatment response and prognosis prediction. We searched publicly available databases and retrieved 465 samples of genes from The Cancer Genome Atlas (TCGA) database and 115 tumor samples from Gene Expression Omnibus (GEO). Meanwhile, we used the ImmPort database to determine the immune-related genes as well. Weighted gene correlation network analysis, Cox regression analysis and least absolute shrinkage and selection operator (LASSO) analysis were used to identify the key immune related genes (IRGs) which are closely related to prognosis. Gene set enrichment analysis (GSEA) was implemented to explore the difference of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway between Immune high- and low-risk score groups. Finally, we made a prognostic nomogram including Immune-Risk score and other clinicopathologic factors. A total of 318 genes from prognosis related modules were identified through weighted gene co-expression network analysis (WGCNA). 46 genes were strongly linked to prognosis after univariate Cox analysis. We constructed a seven genes prognostic signature which showed powerful prediction ability in both training cohort and testing cohort. 16 significant KEGG pathways were identified between high- and low- risk score groups using GSEA analysis. This study identified and verified seven immune-related prognostic biomarkers for the patients with HCC, which have potential value for immune modulatory and therapeutic targets.


2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Wenli Li ◽  
Jun Liu ◽  
Zhanzhong Ma ◽  
Xiaofeng Zhai ◽  
Binbin Cheng ◽  
...  

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and N6-methyladenosine (m6A) is a predominant internal modification of RNA in various cancers. We obtained the expression profiles of m6A-related genes for HCC patients from the International Cancer Genome Consortium and The Cancer Genome Atlas datasets. Most of the m6A RNA methylation regulators were confirmed to be differentially expressed among groups stratified by clinical characteristics and tissues. The clinical factors (including stage, grade, and gender) were correlated with the two subgroups (cluster 1/2). We identified an m6A RNA methylation regulator-based signature (including METTL3, YTHDC2, and YTHDF2) that could effectively stratify a high-risk subset of these patients by univariate and LASSO Cox regression, and receiver operating characteristic (ROC) analysis indicated that the signature had a powerful predictive ability. Immune cell analysis revealed that the genes in the signature were correlated with B cell, CD4 T cell, CD8 T cell, dendritic cell, macrophage, and neutrophil. Functional enrichment analysis suggested that these three genes may be involved in genetic and epigenetic events with known links to HCC. Moreover, the nomogram was established based on the signature integrated with clinicopathological features. The calibration curve and the area under ROC also demonstrated the good performance of the nomogram in predicting 3- and 5-year OS in the ICGC and TCGA cohorts. In summary, we demonstrated the vital role of m6A RNA methylation regulators in the initial presentation and progression of HCC and constructed a nomogram which would predict the clinical outcome and provide a basis for individualized therapy.


2021 ◽  
Vol 2021 ◽  
pp. 1-15
Author(s):  
Feng Xie ◽  
Xiaofeng Liu ◽  
Hua Liu ◽  
Min Wei ◽  
Wei Liu

Background. Advanced cervical carcinoma carries a particularly poor prognosis, and few treatment options exist. It is very important to find a method to evaluate the prognosis and survival rate of cervical carcinoma. The metastasis and invasion of cervical carcinoma are closely related to tumor immune microenvironment (TIME), and immune related genes (IRGs) are involved in the regulation of TIME. However, the role of IRGs in the prognosis of patients with cervical carcinoma remains unclear. Methods. The gene expression profiles of cervical carcinoma were downloaded from The Cancer Genome Atlas (TCGA) database, and IRG information were obtained from the ImmPort database. The IRGs were screened by coexpression analysis and were also performed function enrichment and pathway analyses. A prognosis model was built based on IRGs, and the risk score (RS) was calculated by Cox regression analysis. The accuracy was assessed by receiver operating characteristic (ROC) curve analysis. Besides, the relationship between RS and TIMER-generating immune cell content was performed by immune infiltration analysis. Results. In a total of 2503 differentially expressed genes (DEGs), 204 genes were IRGs, 20 of which were crucially correlated with the survival rate of cervical carcinoma. On the basis of Cox regression analysis, 6 IRGs were included in the prognosis model to calculate the RS. Kaplan-Meier survival and ROC analyses showed that the prognostic function of the model was superior to the current model constructed by clinicopathological risk factors. In addition, these 6 IRG signatures were related to the immune infiltration levels of six immune cells and the overall survival (OS) of cervical carcinoma. Finally, C-terminal Src kinase (CSK) gene is related to tumor metastasis, and Slit guidance ligand 2 (Slit2) is related to tumor clinical stage. Conclusion. The IRGs may contribute to the stratification of prognosis, and CSK/Slit2 may be two suppressor genes for cervical carcinoma.


2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Peng Qin ◽  
Mengyu Zhang ◽  
Xue Liu ◽  
Ziming Dong

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death. HBV infection is an important risk factor for the tumorigenesis of HCC, given that the inflammatory environment is closely related to morbidity and prognosis. Consequently, it is of urgent importance to explore the immunogenomic landscape to supplement the prognosis of HCC. The expression profiles of immune‐related genes (IRGs) were integrated with 377 HCC patients to generate differentially expressed IRGs based on the Cancer Genome Atlas (TCGA) dataset. These IRGs were evaluated and assessed in terms of their diagnostic and prognostic values. A total of 32 differentially expressed immune‐related genes resulted as significantly correlated with the overall survival of HCC patients. The Gene Ontology functional enrichment analysis revealed that these genes were actively involved in cytokine‐cytokine receptor interaction. A prognostic signature based on IRGs (HSPA4, PSME3, PSMD14, FABP6, ISG20L2, TRAF3, NDRG1, NRAS, CSPG5, and IL17D) stratified patients into high-risk versus low-risk groups in terms of overall survival and remained as an independent prognostic factor in multivariate analyses after adjusting for clinical and pathologic factors. Several IRGs (HSPA4, PSME3, PSMD14, FABP6, ISG20L2, TRAF3, NDRG1, NRAS, CSPG5, and IL17D) of clinical significance were screened in the present study, revealing that the proposed clinical-immune signature is a promising risk score for predicting the prognosis of HCC.


2020 ◽  
Author(s):  
Leilei Wang ◽  
Weile Gu ◽  
Huijun Ni

Abstract Papillary renal cell carcinoma (PRCC) is the second most common type of renal carcinoma following clear cell renal cell carcinoma, and the role of immune-related genes (IRGs) in tumorigenesis and metastasis is evident; its prognostic value in PRCC remains unclear. In this study, we downloaded the gene expression profiles and clinical data of patients with PRCC from The Cancer Genome Atlas (TCGA) database and obtained IRGs from the ImmPort database. A total of 371 differentially expressed IRGs (DEIRGs) were discovered between PRCC and normal kidney tissues. Prognostic DEIRGs (PDEIRGs) were identified by univariate Cox regression analysis. Then, we screened the four most representative PDEIRGs (IL13RA2, CCL19, BIRC5, and INHBE) and used them to construct a risk model to predict the prognosis of patients with PRCC. This model precisely stratified survival outcome and accurately identified mutation burden in PRCC. Thus, our results suggest that these four PDEIRGs are available prognostic predictors for PRCC. They could be used to assess the prognosis and to guide individualized treatments for patients with PRCC.


2020 ◽  
Author(s):  
Wen Ye ◽  
Zhehao Shi ◽  
Zhongjing Zhang ◽  
Yi Zhou ◽  
Bicheng Chen ◽  
...  

Abstract Background Hepatocellular carcinoma (HCC) is the most common and deadly type of liver cancer. Autophagy is the process of transporting damaged or aging cellular components into lysosomes for digestion and degradation. There is an accumulative evidence implies that autophagy is a key factor of the progression of cancer. The aim of this study was to determine a panel of a novel autophagy-related prognostic marker for liver cancer. Methods We conducted a comprehensive analysis of ARGs expression profiles and corresponding clinical information based on The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) database. The univariate Cox proportional regression model was used to screen candidate autophagy-related prognostic genes. In addition, the multivariate Cox proportional regression model were helped to prove five key prognostic autophagy-related genes (ATIC, BAX, BIRC5, CAPNS1 and FKBP1A), which were used to construct prognostic signature. Results Based on the prognostic signature, liver cancer patients were significantly divided into high-risk and low-risk groups in terms of overall survival (OS). Further multivariate Cox regression analysis indicated that the prognostic signature remained as an independent prognostic factor for OS. The prognostic signature in possession of a better Area Under Curves (AUC) has a better performance in predicting the survival of patients with HCC, compared with other clinical parameters. Conclusion This study provides a prospective biomarker for monitoring the outcomes in the patients with HCC.


2021 ◽  
Author(s):  
Yuhao Zhang ◽  
Jiaxin Zhang ◽  
Fengxian Wei ◽  
Haodong Zhang ◽  
Dongdong Wang ◽  
...  

Abstract Background: Hepatocellular carcinoma (HCC), which carries a very bad prognosis, is a common malignant tumor worldwide. This study aim to identify a pyroptosis-related long non-coding RNA(pyLncRNA) prognostic signature in HCC by integrated bioinformatics analysis. Methods: All expression profiles of HCC were obtained from The Cancer Genome Atlas (TCGA) and pyroptosis-related genes were from the GSEA website. After identified differentially expressed pyLncRNAs, univariate Cox regression and Lasso analysis were used to identify a pyroptosis-related LncRNAs prognositic signature(py-LPS). Internal validation was used to validate the prognostic value of the py-LPS via the Kaplan-Meier(K-M) curve and receiver operating characteristic(ROC) curve. Additional, we established the nomogram and analyzed the correlation between the signature and immune immune infiltration as well as clinical treatment. Result: 7 pyLncRNAs were established the signature for HCC prognosis. K-M curves exhibited the low risk group presented a markedly longer OS than the high. Clinical subgroups analysis based age, gender, grade and stage yielded the similar results. The signature had an independent prognostic value for HCC(p<0.001). Nomogram estimated one-, three- and five-year survival were 0.777, 0.741 and 0.709. Then, gene set enrichment analysis(GSEA) demostrated significant pathways. Futhermore, we found immune cell infiltration and immunotherapy targets was associated with the signature,which could provided clinical recommendations for chemotherapy.Conclusion: In this study, a novel pyroptosis-related LncRNAs porgnostic signature of HCC, correlated with immune infiltration, could predict the survival of HCC patients and give suggestions for clinical treatment.


Sign in / Sign up

Export Citation Format

Share Document